Bone Marrow Transplantation – Pipeline Review, H2 2012
出 版 商：Global Markets Direct
出版日期：2012/08/31
頁 數：50頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Bone Marrow Transplantation – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Bone Marrow Transplantation - Pipeline Review, H2 2012', provides an overview of the Bone Marrow Transplantation therapeutic pipeline. This report provides information on the therapeutic development for Bone Marrow Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation. 'Bone Marrow Transplantation - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Bone Marrow Transplantation.
- A review of the Bone Marrow Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bone Marrow Transplantation pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Bone Marrow Transplantation.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bone Marrow Transplantation pipeline depth and focus of Bone Marrow Transplantation therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Summary
Global Markets Direct’s, 'Bone Marrow Transplantation - Pipeline Review, H2 2012', provides an overview of the Bone Marrow Transplantation therapeutic pipeline. This report provides information on the therapeutic development for Bone Marrow Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation. 'Bone Marrow Transplantation - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Bone Marrow Transplantation.
- A review of the Bone Marrow Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bone Marrow Transplantation pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Bone Marrow Transplantation.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bone Marrow Transplantation pipeline depth and focus of Bone Marrow Transplantation therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Bone Marrow Transplantation Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Bone Marrow Transplantation 7
Bone Marrow Transplantation Therapeutics under Development by Companies 9
Bone Marrow Transplantation Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Bone Marrow Transplantation Therapeutics – Products under Development by Companies 15
Bone Marrow Transplantation Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Bone Marrow Transplantation Therapeutics Development 17
Cleveland BioLabs, Inc. 17
Pluristem Therapeutics Inc. 18
Cytheris SA 19
Bone Marrow Transplantation – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
Protectan CBLB612 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
CYT-107 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
MEDI-507 + Cyclosporine A + Rituximab + Corticosteroids - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Busulfan + Fludarabine + Anti-Thymocyte Globulin + Stem Cell Transplant + Total Lymphoid Irradiation - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 31
Therapeutic Allogeneic Lymphocytes + Cyclophosphamide + Cyclosporine + Etoposide + Fludarabine Phosphate + Stem Cell Transplantation + Radiation Therapy - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 33
Cyclophosphamide + Fludarabine + Anti Thymocyte Globulin - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Adjuvant For UCB Transplantation - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
PLX-BMP - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Bone Marrow Transplantation Therapeutics – Drug Profile Updates 39
Bone Marrow Transplantation Therapeutics - Dormant Products 41
Bone Marrow Transplantation – Product Development Milestones 42
Featured News & Press Releases 42
Aug 06, 2012: Pluristem's PLX Cells Save Life Of Cancer Patient Suffering From Bone Marrow Failure 42
May 09, 2012: Pluristem's PLX Cells Saves Life Of Child After Bone Marrow Transplantation Failure 42
Feb 01, 2012: Ligand Presents Successful Phase II Results For Captisol-Enabled, Propylene Glycol-Free Melphalan At BMT Tandem Meetings 43
Jul 07, 2011: Mesoblast Receives FDA Clearance For Phase III Bone Marrow Transplant Trial 45
May 10, 2010: AiCuris Provides Update On Phase IIb Trial Of AIC246 46
Mar 30, 2010: YM BioSciences Announces Early Expansion Of Ongoing CYT387 Phase I/II Clinical Study Based On Favorable Safety And Activity Data 46
Jun 23, 2008: Astellas submit an sNDA for the immunosuppressant Prograf for Ulcerative Colitis in Japan 47
May 21, 2004: SuperGen Announces Study Of Novel Regimen Using Nipent For Hematopoietic Stem Cell Transplantation Published In Journal Of Bone Marrow Transplantation 47
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 50
Disclaimer 50
List of Tables
Number of Products Under Development for Bone Marrow Transplantation, H2 2012 7
Products under Development for Bone Marrow Transplantation – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Cleveland BioLabs, Inc., H2 2012 17
Pluristem Therapeutics Inc., H2 2012 18
Cytheris SA, H2 2012 19
Assessment by Monotherapy Products, H2 2012 20
Assessment by Combination Products, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 25
Bone Marrow Transplantation Therapeutics – Drug Profile Updates 39
Bone Marrow Transplantation Therapeutics – Dormant Products 41
List of Figures
Number of Products under Development for Bone Marrow Transplantation, H2 2012 7
Products under Development for Bone Marrow Transplantation – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 20
Assessment by Combination Products, H2 2012 21
Assessment by Route of Administration, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 23
Assessment by Molecule Type, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 25
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Bone Marrow Transplantation Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Bone Marrow Transplantation 7
Bone Marrow Transplantation Therapeutics under Development by Companies 9
Bone Marrow Transplantation Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Bone Marrow Transplantation Therapeutics – Products under Development by Companies 15
Bone Marrow Transplantation Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Bone Marrow Transplantation Therapeutics Development 17
Cleveland BioLabs, Inc. 17
Pluristem Therapeutics Inc. 18
Cytheris SA 19
Bone Marrow Transplantation – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
Protectan CBLB612 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
CYT-107 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
MEDI-507 + Cyclosporine A + Rituximab + Corticosteroids - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Busulfan + Fludarabine + Anti-Thymocyte Globulin + Stem Cell Transplant + Total Lymphoid Irradiation - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 31
Therapeutic Allogeneic Lymphocytes + Cyclophosphamide + Cyclosporine + Etoposide + Fludarabine Phosphate + Stem Cell Transplantation + Radiation Therapy - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 33
Cyclophosphamide + Fludarabine + Anti Thymocyte Globulin - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Adjuvant For UCB Transplantation - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
PLX-BMP - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Bone Marrow Transplantation Therapeutics – Drug Profile Updates 39
Bone Marrow Transplantation Therapeutics - Dormant Products 41
Bone Marrow Transplantation – Product Development Milestones 42
Featured News & Press Releases 42
Aug 06, 2012: Pluristem's PLX Cells Save Life Of Cancer Patient Suffering From Bone Marrow Failure 42
May 09, 2012: Pluristem's PLX Cells Saves Life Of Child After Bone Marrow Transplantation Failure 42
Feb 01, 2012: Ligand Presents Successful Phase II Results For Captisol-Enabled, Propylene Glycol-Free Melphalan At BMT Tandem Meetings 43
Jul 07, 2011: Mesoblast Receives FDA Clearance For Phase III Bone Marrow Transplant Trial 45
May 10, 2010: AiCuris Provides Update On Phase IIb Trial Of AIC246 46
Mar 30, 2010: YM BioSciences Announces Early Expansion Of Ongoing CYT387 Phase I/II Clinical Study Based On Favorable Safety And Activity Data 46
Jun 23, 2008: Astellas submit an sNDA for the immunosuppressant Prograf for Ulcerative Colitis in Japan 47
May 21, 2004: SuperGen Announces Study Of Novel Regimen Using Nipent For Hematopoietic Stem Cell Transplantation Published In Journal Of Bone Marrow Transplantation 47
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 50
Disclaimer 50
List of Tables
Number of Products Under Development for Bone Marrow Transplantation, H2 2012 7
Products under Development for Bone Marrow Transplantation – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Cleveland BioLabs, Inc., H2 2012 17
Pluristem Therapeutics Inc., H2 2012 18
Cytheris SA, H2 2012 19
Assessment by Monotherapy Products, H2 2012 20
Assessment by Combination Products, H2 2012 21
Assessment by Stage and Route of Administration, H2 2012 23
Assessment by Stage and Molecule Type, H2 2012 25
Bone Marrow Transplantation Therapeutics – Drug Profile Updates 39
Bone Marrow Transplantation Therapeutics – Dormant Products 41
List of Figures
Number of Products under Development for Bone Marrow Transplantation, H2 2012 7
Products under Development for Bone Marrow Transplantation – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 20
Assessment by Combination Products, H2 2012 21
Assessment by Route of Administration, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 23
Assessment by Molecule Type, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 25
